
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Word of the new ICD-10 compliance deadline came as welcome news to many in the healthcare realm — just not everyone.
There remains a corner of the industry that publicly asked the Department of Health and Human Services (HHS) to consider other alternatives, most notably ICD-11, before mandating a new deadline.
Read the full story:
Source: Healthcare Finance News






